Emulate Stock
Organs-on-Chips Company
Sign up today and learn more about Emulate Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Emulate Stock
Emulate develops Organs-on-Chips technologies through an automated human bioemulation platform that aims to mimic true human physiology so that responses to medicines, chemicals, and diseases can be accurately predicted. Through co-innovation with collaborators and internal programs, Emulate aims to advance product innovation, design, and safety across a range of applications in drug development, personalized medicine, agriculture, and chemical-based consumer products.
Emulate was founded in 2013 and is based in Bostom, MA. Notable investors in Emulate include Founders Fund, Glass Wall Syndicate, and Starlight Ventures.
Investors
ALS Finding a Cure
ALS Investment Fund
Alumni Ventures Group
Lacework, Getaround, GrubMarket, Better.com, Groq, Divergent 3D, SonderMind, Plastiq, Accolade, Madison Reed
ATEL Ventures
Blue Ivy Ventures
Wheels Up, Divergent 3D, Plastiq, Upstart, Humatics, Emulate, Shift, OpenGov, Tamr, Freshly
Cedars Sinai Medical Center
Founders Fund
Lyft, SpaceX, Spotify, Airbnb, Stripe, Anduril Industries, Flexport, Palantir Technologies, Wish, Compass
Glass Wall Syndicate
LabCorp
NanoDimension
National Institutes of Health
Northpond Ventures
OS Fund
Pivot Bio, Emulate, Tempo Automation, Human Longevity, Verge Genomics, Elysium Health, uBiome, 3T Biosciences
Perceptive Advisors
Zymergen, Freenome, Omada Health, Crossover Health, Twin Health, Emulate, PROCEPT BioRobotics, AEGEA Medical, Saama
SciFi VC
Zymergen, PsiQuantum, Anchorage Digital, Synthego, Virta Health, Emulate
Starlight Ventures
Techammer
DataRobot, Cityblock Health, EverlyWell, Imperfect Foods, Emulate, Pymetrics
Funding History
| July 2014 | $12.0M |
|---|---|
| March 2016 | $45.0M |
| June 2018 | $36.0M |
| August 2019 | $28.2M |
| August 2021 | $20.7M |
| August 2021 | $60.4M |
Management
Chief Executive Officer
Jim Corbett
Chief Financial Officer
Scott Kantor
Press
biospace - Nov, 17 2021
EMulate Therapeutics Announces the Incorporation of Two Wholly Owned SubsidiariesTechCrunch - Sep, 8 2021
Emulate Inc closes $82M Series E to fund expansion of “organ-on-a-chip” productsmedcitynews - Aug, 25 2021
Emulate CEO shares the organ-chip maker’s vision to understand and predict drug responsedrugdiscoverytrends - Mar, 18 2021
Why Emulate launched a colon intestine chipPR Newswire - Jan, 11 2021
Organ-On-Chip (OOC) Market Size is USD 303.6 Million by 2026 at CAGR 39.9%PR Newswire - Jan, 8 2021
Emulate Announces Organ-on-a-Chip Application and Services RoadmapBio Space - Dec, 21 2020
Emulate Unveils Brain-Chip to Enhance Neuroinflammatory Disease Research and Drug DiscoveryPR Newswire - Dec, 8 2020
Emulate Announces Lung-Chip Technology Used by U.S. Army to Study Effects of COVID-19Technology Networks - Nov, 24 2020
Engineering Mucosal Barriers: From Organoids to Organs-on-Chipsxconomy - Mar, 23 2020
Emulate Taps PerkinElmer’s Corbett as CEO, Gets Cash for Commercial Pusheurekalert - Mar, 19 2020
Organ-chip platform enables new insights into human diseases and toxicity mechanismsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
